Menu
Recruiting NCT06718569

Pain in Inflammatory Joint Diseases

— Observational Arthritis Arthritis, Juvenile Idiopathic Arthritis,Rheumatoid Arthritis, Reactive

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Biological or targeted synthetic DMARD.
Who it may be relevant to
Registry conditions: Arthritis, Arthritis, Juvenile Idiopathic, Arthritis,Rheumatoid, Arthritis, Reactive. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Norway
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Advancing the Understanding of Pain Mechanisms in Inflammatory Arthritis Towards Precision Pain Management

Overview

Our primary objective is to better understand the etiology and consequences of chronic paint by using an explorative approach to identify phenotypes and endotypes of patients with inflammatory joint diseases, with a special focus on central sensitization and cognitive functioning as a key element in chronic pain. We will also examine the risk factors and clinical impact of these factors on pain, disease activity and treatment effects in a longitudinal study of patients with inflammatory joint disesases.

Interventions

  • Drug Biological or targeted synthetic DMARD
    All biological or targeted synthetic DMARDs that are available for treatment of patients with inflammatory joint diseases

Primary outcome measures

  • PROMIS Pain Interference - Short Form 8a [Time frame: Baseline, 3 months]
Secondary outcome measures (12)
  • Social network [Time frame: Baseline]
  • Gender role perception [Time frame: Baseline]
  • Arthritis Self-Efficacy Scale (ASES) [Time frame: Baseline]
  • Pain Catastrophizing Scale (PSC) [Time frame: Baseline]
  • Douleur Neuropathique 4 (DN4) [Time frame: Baseline and 3 months]
  • Painful joint count (Homunculus) [Time frame: Baseline and 3 months]
  • Patient Health Questionnaire (PHQ) [Time frame: Baseline]
  • General Anxiety Disorder Questionnaire (GAD-7) [Time frame: Baseline]
  • Psoriatic Arthritis Impact of Disease (PsAID) [Time frame: Baseline and 3 months]
  • MetaCognitions Questionnaire 30* (MCQ-30) [Time frame: Baseline]
  • Pain Metacognition Questionnaire (PMQ) [Time frame: Baseline and 3 months]
  • Everyday Memory Questionnaire - revised (EMQ) [Time frame: Baseline and 3 months]

Eligibility criteria

Inclusion criteria

  • All patients who initiate or switch biological or targeted synthetic DMARDs

Exclusion criteria

  • None

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

Norway · 1 center
  • Diakonhjemmet Hospital — Oslo

Identifiers

NCT: NCT06718569 · DS-00850 · 708967

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗